Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

被引：1
|
作者：
Houghton, Peter J. [1 ]
Kurmasheva, Raushan T. [1 ]
Gorlick, Richard [2 ]
Kolb, E. Anders [3 ]
Mosse, Yael P. [4 ]
Erickson, Stephen W. [5 ]
Guo, Yuelong [5 ]
Teicher, Beverly A. [6 ]
Smith, Malcolm A. [6 ]
Maris, John M. [4 ]
机构：
[1] Greehey Childrens Canc Res Inst, San Antonio, TX USA
[2] MD Anderson, Houston, TX USA
[3] Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA
[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[5] RTI Int, Res Triangle Pk, NC USA
[6] NCI, Bethesda, MD 20892 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-LB-B15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-B15
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report
    Kolb, E. Anders
    Houghton, Peter J.
    Kurmasheva, Raushan T.
    Mosse, Yael P.
    Maris, John M.
    Erickson, Stephen W.
    Guo, Yuelong
    Teicher, Beverly A.
    Smith, Malcolm A.
    Gorlick, Richard
    PEDIATRIC BLOOD & CANCER, 2020, 67 (05)
  • [2] PRECLINICAL STUDIES OF DIANHYDROGALACTITOL (VAL-083) IN DIPG, AS SINGLE AGENT OR AS A COMBINATION WITH RADIATION OR AZD1775
    Steino, Anne
    Bacha, Jeffrey
    Brown, Dennis
    Mueller, Sabine
    NEURO-ONCOLOGY, 2018, 20 : 60 - 60
  • [3] Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
    Cole, Kristina A.
    Ijaz, Heba
    Surrey, Lea F.
    Santi, Mariarita
    Liu, Xiaowei
    Minard, Charles G.
    Maris, John M.
    Voss, Stephan
    Reid, Joel M.
    Fox, Elizabeth
    Weigel, Brenda J.
    CANCER, 2023, 129 (14) : 2245 - 2255
  • [4] VAL-083 IN COMBINATION WITH AZD1775 FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
    Subramaniam, Bavani
    Roy, Debasish
    Woldegerima, Ayda
    Przystal, Justyna
    Zhang, Jie
    Laternser, Sandra
    Kritzer, Bettina
    Yadavilli, Sridevi
    Mueller, Sabine
    Packer, Roger
    Nazarian, Javad
    NEURO-ONCOLOGY, 2024, 26
  • [5] A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.
    Hamilton, Erika Paige
    Wang, Judy Sing-Zan
    Falchook, Gerald
    Jones, Suzanne Fields
    Cook, Carl
    Mugundu, Ganesh
    Jewsbury, Philip John
    O'Connor, Mark J.
    Pierce, Andrewi
    Li, Bob T.
    Oza, Amit M.
    Infante, Jeffrey R.
    Burris, Howard A.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
    Wright, Gabriela
    Golubeva, Volha
    Rix, Lily L. Remsing
    Bemdt, Norbert
    Luo, Yunting
    Ward, Grace A.
    Gray, Jhanelle E.
    Schonbrunn, Ernst
    Lawrence, Harshani R.
    Monteiro, Alvaro N. A.
    Rix, Uwe
    ACS CHEMICAL BIOLOGY, 2017, 12 (07) : 1883 - 1892
  • [7] Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
    Do, Khanh
    Wilsker, Deborah
    Ji, Jiuping
    Zlott, Jennifer
    Freshwater, Tomoko
    Kinders, Robert J.
    Collins, Jerry
    Chen, Alice P.
    Doroshow, James H.
    Kummar, Shivaani
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3409 - +
  • [8] Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)
    Houghton, P. J.
    Kurmasheva, R. T.
    Erickson, S.
    Smith, M. A.
    Lock, R. B.
    Evans, K.
    Toscan, C.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S18 - S18
  • [9] Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312).
    Cole, Kristina A.
    Ijaz, Heba
    Surrey, Lea
    Santi-Vicini, Mariarita
    Liu, Xiaowei
    Minard, Charles G.
    Maris, John M.
    Voss, Stephan
    Fox, Elizabeth
    Weigal, Brenda
    CANCER RESEARCH, 2021, 81 (13)
  • [10] A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells
    Matheson, Christopher J.
    Venkataraman, Sujatha
    Amani, Vladimir
    Harris, Peter S.
    Backos, Donald S.
    Donson, Andrew M.
    Wempe, Michael F.
    Foreman, Nicholas K.
    Vibhakar, Rajeev
    Reigan, Philip
    ACS CHEMICAL BIOLOGY, 2016, 11 (04) : 921 - 930
12345